BioNTech’s New Chapter: From COVID-19 Success to Cancer Treatment Ambitions Amid Financial Challenges
BioNTech faces a decline in Q4 2024 profits, with earnings per share dropping from €1.90 to €1.08, yet exceeding market expectations. Revenue falls from €1.479 billion to €1.19 billion as…